Space-making particle therapy for sarcomas derived from the abdominopelvic region

•Space-making particle therapy provides a rational combination treatment.•Effectiveness of space-making particle therapy has been demonstrated. The primary definitive treatment for abdominopelvic sarcomas (APSs) is resection, although incomplete resection has a negative prognostic impact. Although t...

Full description

Saved in:
Bibliographic Details
Published in:Radiotherapy and oncology 2020-05, Vol.146, p.194-199
Main Authors: Komatsu, Shohei, Demizu, Yusuke, Sulaiman, Nor Shazrina, Terashima, Kazuki, Suga, Masaki, Kido, Masahiro, Toyama, Hirochika, Tokumaru, Sunao, Okimoto, Tomoaki, Sasaki, Ryohei, Fukumoto, Takumi
Format: Article
Language:English
Subjects:
Abdominopelvic sarcoma
Combined Modality Therapy
Dosimetric evaluation
Humans
Particle therapy
Prognosis
Sarcoma - radiotherapy
Sarcoma - surgery
Soft Tissue Neoplasms
Surgical spacer placement
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•Space-making particle therapy provides a rational combination treatment.•Effectiveness of space-making particle therapy has been demonstrated. The primary definitive treatment for abdominopelvic sarcomas (APSs) is resection, although incomplete resection has a negative prognostic impact. Although the effectiveness of particle therapy (PT) as a treatment for APS has already been demonstrated, its application for tumors adjacent to the gastrointestinal tract is frequently restricted, due to extremely low tolerance. Space-making PT, consisting of surgical spacer placement and subsequent PT, has been developed to overcome this limitation. Between June 2006 and June 2018, a total of 75 patients with 12 types of APS underwent space-making PT. The 3-year local control rate of all patients was 90.3%. Fourteen surgery-related complications were observed in 12 patients (16%), and complications of Grade 3b or higher were observed in 3 patients. Ninety-five PT-related complications were seen in 66 patients (88.0%), and 13 patients (17.3%) had complications of Grade 3 or higher. The median V95% (volume irradiated with 95% of the treatment planning dose) of the gross tumor volume and clinical target volume were 99.9% and 99.5%, respectively. The median D95% (dose intensity covering 95% of the target volume) of the gross tumor volume/planned dose and clinical target volume/planned dose were 99.4%, and 99.1%, respectively. The feasibility and effectiveness of space-making PT have been demonstrated via dosimetric evaluation, and our results indicate that this new strategy may potentially provide an effective and innovative treatment option for advanced APS.
ISSN:0167-8140
1879-0887
DOI:10.1016/j.radonc.2020.02.021